Hypoalbuminaemia in Ulcerative Colitis and Certain Forms of Enteritis Clinical and Pathophysiological Aspects

Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment

BACKGROUND

Up to 60% of patients with ulcerative colitis (UC) ultimately fail anti-tumor necrosis factor (TNF) treatment. We aimed to investigate early predictive markers of clinical and endoscopic outcomes in patients with UC who were anti-TNF-naïve commencing anti-TNF treatment, with particular focus on changes in albumin and C-reactive protein levels in the first 2 weeks of treatment.

METHODS

We retrospectively investigated 210 patients with UC who started infliximab or adalimumab between 2009 and 2016 (male, 62.4%; median age at diagnosis, 37.9 years [interquartile range, 25.5-48.9 years]; median follow-up duration, 3.3 years [1.9-5.0 years]). Logistic and Cox proportional-hazards regressions were performed to identify variables associated with primary nonresponse (PNR), endoscopic outcomes, time-to-colectomy, and anti-TNF failure.

RESULTS

Forty-one patients (19.5%) experienced PNR; week 0/week 2 ratio serum albumin was associated with PNR (adjusted odds ratio [aOR], 1.8; 95% confidence interval [CI], 1.1-2.9, per interquartile range increase). Week 0/week 2 ratio albumin was also associated with endoscopic response (aOR, 0.28; 95% CI, 0.31-0.82) and endoscopic remission (aOR, 0.61; 95% CI, 0.39-0.96) at weeks 8 to 14, time-to-colectomy (adjusted hazard ratio, 2.12; 95% CI, 1.29-3.49) and time-to-anti-TNF failure (adjusted hazard ratio, 1.54; 95% CI, 1.22-1.96), regardless of age, disease severity, or in-patient status. Association with time-to-colectomy and anti-TNF failure was externally validated in an independent cohort of inpatients with UC starting infliximab.

CONCLUSIONS

Change in serum albumin within the first 2 weeks of anti-TNF treatment is predictive of PNR, endoscopic outcomes, time-to-colectomy, and anti-TNF failure in patients with UC. Timely access to this biomarker enables early identification of patients with UC at risk of anti-TNF failure and may guide early optimization of anti-TNF treatment to improve disease outcomes.

Streptokinase treatment of deep venous thrombosis of the lower extremity. Clinical, phlebographic and plethysmographic evaluation of early and late results

The investigation comprises 19 patients with acute deep vein thrombosis of the leg treated with streptokinase. The acute clinical symptoms rapidly subsided in 15 patients. Phlebography, performed immediately after treatment, revealed complete thrombus regression in 7 cases, restoration of venous flow but remnants of thrombi in 4 and no effect in 7. One woman was not evaluated radiologically due to pregnancy. The phlebographic restoration seemed to be correlated to the duration of the thrombotic symptoms. Follow-up examinations 6-50 months after the thrombotic incident demonstrated normal phlebograms in 8 patients, all of whom were also free from post-thrombotic symptoms. Venous occlusion plethysmography confirmed that these patients had a normal venous outflow capacity and valvular function in the relevant limbs. By contrast, the remaining 11 patients, with more or less extensive remnants of thrombi at the follow-up phlebography, were found to have plethysmographic signs of venous obstruction and sometimes also valvular insufficiency. The results indicate that thrombolytic treatment is able to give a complete and lasting anatomical and functional restitution of the deep veins after an acute thrombosis in the leg, provided that treatment is induced early enough.

Antiinflammatory treatment and intestinal alpha 1-antitrypsin clearance in active Crohn's disease

Intestinal alpha 1-antitrypsin clearance was quantified in 17 patients with clinically active Crohn's disease before and after a six-week period of treatment with sulfasalazine and methylprednisolone. Before the study, alpha 1-antitrypsin clearance and, hence, enteric protein loss was elevated as being above control values in 16 patients. After therapy, clearance values decreased in 11 and were normalized in five patients. Serum albumin level was normalized in 11 of 12 patients who had hypoalbuminemia before the study. Clinical condition was improved in all but 1 patient after treatment. There was no close correlation between alpha 1-antitrypsin clearance and disease activity index. These results indicate that antiinflammatory therapy has a beneficial effect on enteric protein loss in Crohn's disease. The measurement of alpha 1-antitrypsin clearance provides a useful adjunctive technique in evaluating intestinal inflammatory activity, and it seems to be of use in following the efficacy of treatment in the course of illness in Crohn's disease.

The thyroid in ulcerative colitis and Crohn's disease. IV. Thyroid hormone binding proteins

The thyroxine binding globulin (TBG), thyroxine binding prealbumin (TBPA), albumin, thyroxine (T(4)) and the triiodothyronine uptake test (T(3)-test) values have been estimated in serum of twenty patients with ulcerative colitis (UC) or Crohn's disease. The patient group was compared with twenty healthy control subjects matched for sex and age. The T(4) and the T(3)-test values were similar in the two groups. TBPA and albumin in serum were significantly lower, while the TBG values were significantly higher in the patients than in the controls. Treatment with corticosteroids influenced the results significantly. It is also concluded that in UC and Crohn's disease sometimes both the T(4) and the T(3)-test values can be abnormal so that misdiagnosis of hyperthyroidism is easy to make.